Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record, with a small difference in title or year; 41 of the 41 references it cites were found in a registry or an index.

Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease: A Meta-Analysis of Patient-Level Data

Jafar, Tazeen H., Schmid, Christopher H., Landa, Marcia, Giatras, Ioannis, Toto, Robert, Remuzzi, Giuseppe, Maschio, Giuseppe, Brenner, Barry M., Kamper, Annelise, Zucchelli, Pietro, Becker, Gavin, Himmelmann, Andres, Bannister, Kym, Landais, Paul, Shahinfar, Shahnaz, de Jong, Paul E., de Zeeuw, Dick, Lau, Joseph, Levey, Andrew S., and the ACE Inhibition in Progressive Renal Disease Study Group*·2001·Annals of Internal Medicine

Abstract

PURPOSE: To examine the efficacy of ACE inhibitors for treatment of nondiabetic renal disease. DATA SOURCES: 11 randomized, controlled trials comparing the efficacy of antihypertensive regimens including ACE inhibitors to the efficacy of regimens without ACE inhibitors in predominantly nondiabetic renal disease. STUDY SELECTION: Studies were identified by searching the MEDLINE database for English-language studies evaluating the effects of ACE inhibitors on renal disease in humans between May 1977 (when ACE inhibitors were approved for trials in humans) and September 1997. DATA EXTRACTION: Data on 1860 nondiabetic patients were analyzed. DATA SYNTHESIS: Mean duration of follow-up was 2.2 years. Patients in the ACE inhibitor group had a greater mean decrease in systolic and diastolic blood pressure (4.5 mm Hg [95% CI, 3.0 to 6.1 mm Hg]) and 2.3 mm Hg [CI, 1.4 to 3.2 mm Hg], respectively) and urinary protein excretion (0.46 g/d [CI, 0.33 to 0.59 g/d]). After adjustment for patient and study characteristics at baseline and changes in systolic blood pressure and urinary protein excretion during follow-up, relative risks in the ACE inhibitor group were 0.69 (CI, 0.51 to 0.94) for end-stage renal disease and 0.70 (CI, 0.55 to 0.88) for the combined outcome of doubling of the baseline serum creatinine concentration or end-stage renal disease. Patients with greater urinary protein excretion at baseline benefited more from ACE inhibitor therapy (P = 0.03 and P = 0.001, respectively), but the data were inconclusive as to whether the benefit extended to patients with baseline urinary protein excretion less than 0.5 g/d. CONCLUSION: Antihypertensive regimens that include ACE inhibitors are more effective than regimens without ACE inhibitors in slowing the progression of nondiabetic renal disease. The beneficial effect of ACE inhibitors is mediated by factors in addition to decreasing blood pressure and urinary protein excretion and is greater in patients with proteinuria. Angiotensin-converting inhibitors are indicated for treatment of nondiabetic patients with chronic renal disease and proteinuria and, possibly, those without proteinuria.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-135-2-200107170-00007

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Research works printed but not linked: 4

  1. Mosconi L, 1996, Kidney Int Suppl, 55, S91
  2. van Essen GG, 1997, Kidney Int Suppl, 63, S58
  3. 10.1001/archinte.1996.00440060016002 · doi:10.1001/archinte.1996.00440060016002
  4. Berggåard I, 1970, Lakartidningen, 67, 5798

Cited by

See all 1,092

Metadata

Authors
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., Becker, G., Himmelmann, A., Bannister, K., Landais, P., Shahinfar, S., de Jong, P. E., de Zeeuw, D., Lau, J., Levey, A. S., & and the ACE Inhibition in Progressive Renal Disease Study Group*
Affiliations
  • Tufts University (US)
  • From New England Medical Center, Tufts University School of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; University of Texas at Southwestern, Dallas, Texas; Institute di Recherche, Farmacologiche “Mario Negri,” Bergamo, Ospedale Civile Maggiore, Verona, and Ospedale M. Malphigi, Bologna, Italy; Herlev Hospital, University of Copenhagen, Copenhagen, Denmark;
Corresponding author
Jafar, Tazeen H.
Venue
Annals of Internal Medicine
Published
2001-07-17
Volume
135
Issue
2
Pages
73-87
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2170453602
Cited by
1,092
References
41
Citations by year
2026: 13 · 2025: 21 · 2024: 28 · 2023: 39 · 2022: 17 · 2021: 30 · 2020: 34 · 2019: 24 · 2018: 22 · 2017: 26 · 2016: 24 · 2015: 35 · 2014: 40 · 2013: 36 · 2012: 62
FWCI
50.86
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
  • Agency for Healthcare Research and Quality (R01 HS 10064, HS08532)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK53869A, R01DK053869)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords
ACE inhibitors, non-diabetic kidney disease, chronic kidney disease progression, proteinuria, blood pressure reduction, urinary protein excretion, end-stage renal disease, antihypertensive therapy, serum creatinine doubling
MeSH terms
Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Creatinine, Diabetes Mellitus, Follow-Up Studies, Humans, Hypertension, Kidney Diseases, Kidney Failure, Chronic, Proteinuria, Sensitivity and Specificity, Logistic Models, Proportional Hazards Models, Randomized Controlled Trials as Topic, Treatment Outcome, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease: A Meta-Analysis of Patient-Level Data. https://app.cochat.ai/papers/10.7326/0003-4819-135-2-200107170-00007
The paper
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., Becker, G., Himmelmann, A., Bannister, K., Landais, P., Shahinfar, S., de Jong, P. E., de Zeeuw, D., Lau, J., Levey, A. S., & and the ACE Inhibition in Progressive Renal Disease Study Group*. (2001). Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease: A Meta-Analysis of Patient-Level Data. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-135-2-200107170-00007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.